Anne M. Vanlent

ANNE M. VANLENT joined Barrier Therapeutics, Inc. as Executive Vice
President and Chief Financial Officer in May 2002, concurrent with the
closing of the initial $46 million financing. Ms. VanLent brings to
Barrier 20 years of senior management experience with both public and
private emerging growth companies in healthcare and technology. Prior to
joining Barrier, she was Executive Vice President, Portfolio Management,
for Sarnoff Corporation where she directed Sarnoff’s venture spinoff
process and was in charge of all patent and licensing activities. From
the early 1980s until joining Sarnoff in 1997, Ms VanLent held senior
management positions in or consulted for a number of emerging growth
healthcare companies. She served as Chief Financial Officer for The
Liposome Company, Inc. (now part of Elan Pharmaceuticals) from 1985
until 1992, where she was involved with the its initial public offering
as well as several other public and private financings. She also served
as EVP and CFO for an early stage neuroscience company, Trophix
Pharmaceuticals, Inc., which was purchased by Allelix, and consulted
with several other private companies. Ms. VanLent is a member of the
Board of Directors of Penwest Pharmaceuticals and i-STAT Corporation.
She holds a Bachelor of Science degree from Mount Holyoke College in
Physics and did graduate work in Biophysics.